LYSOCLEAR
Lysoclear, Inc. is a pre-clinical Ichor Therapeutics portfolio company that develops enzyme therapies for eye disease. The company is currently developing leads to treat atrophic “dry” age-related macular degeneration and Stargardt’s macular degeneration.
LYSOCLEAR
Industry:
Biotechnology Life Science
Founded:
2016-01-01
Address:
Lafayette, Louisiana, United States
Country:
United States
Website Url:
http://www.lysoclear.com
Total Employee:
1+
Status:
Active
Contact:
(518) 420-5004
Total Funding:
3 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Amazon Office 365 Mail Microsoft Azure DNS GoDaddy DNS Google Google Cloud AWS Global Accelerator WP Engine
Similar Organizations
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Renovacor
Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapy‑based treatments for cardiovascular disease.
Investors List
Grapeseed.Bio
Grapeseed.Bio investment in Venture Round - Lysoclear
KIZOO Technology Capital
KIZOO Technology Capital investment in Seed Round - Lysoclear
Official Site Inspections
http://www.lysoclear.com
- Host name: 178.108.62.166.host.secureserver.net
- IP address: 166.62.108.178
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Lysoclear"
LYSOCLEAR for treating macular degeneration - lifespan
LYSOCLEAR is an enzyme product that can enter the lysosomes of retinal pigmented epithelial (RPE) cells, where A2E accumulates, and destroy it. Ongoing studies suggest that …See details»
About Us - Ichor Life Sciences
Lysoclear, Inc. is developing a recombinant enzyme therapy that targets retinoid derivatives thought to contribute to various eye diseases. Looking for a discovery partner? Contact UsSee details»
Lysoclear - Crunchbase Company Profile & Funding
Lysoclear, Inc. is a pre-clinical Ichor Therapeutics portfolio company that develops enzyme therapies for eye disease. The company is currently developing leads to treat atrophic “dry” …See details»
Ichor Therapeutics announces series A offering for LYSOCLEAR to …
In 2017 Ichor announced LYSOCLEAR, a recombinant enzyme product that selectively localizes to the lysosomes of RPE cells where A2E accumulates, and destroys it. Ongoing studies …See details»
Ichor CEO delivers workshop and Lysoclear update at …
Jul 12, 2019 · On the second day of the conference, Dr. Kelsey Moody presented a research update on Lysoclear’s enzyme augmentation therapy (EAT) for macular degeneration. This research may lead to new treatments for the …See details»
Kelsey Moody – Developing a Therapy for Age Related …
Mar 13, 2017 · How easy (or difficult) would it be to adapt LYSOCLEAR to target different types of waste products in lysosomes of different tissues? The idea of LYSOCLEAR is based on enzyme replacement therapy, which has already …See details»
Ichors doctoral program training new scientists
May 16, 2023 · Since that time, Kris has led efforts to develop an enzyme therapy for age-related macular degeneration and Stargardt’s disease at Ichor’s portfolio company Lysoclear.See details»
An Interview with Kelsey Moody of Ichor Therapeutics
Mar 15, 2017 · Moody's focus in the past few years has been developing an effective treatment for age-related macular degeneration (AMD), a leading cause of vision loss among people …See details»
Lysoclear - Funding, Financials, Valuation & Investors - Crunchbase
Lysoclear is a pre-clinical Ichor Therapeutics portfolio company that develops enzyme therapies for eye disease.See details»
Ichor CEO presents at GIANT Health event - Ichor Life …
Oct 22, 2019 · Lysoclear is developing an enzyme therapy to treat both age-related macular degeneration and Stargardt’s disease. Today, more than 200 million people worldwide are affected by these diseases. In 2018, Lysoclear …See details»
Ichor Therapeutics Announces Lysoclear SENS Rejuvenation …
Feb 15, 2017 · Lysoclear is safe and effective at breaking down toxic A2E, removing up to 10% with each dose. Lysoclear selectively localizes to the lysosomes of retinal pigmented epithelial …See details»
LYSOCLEAR for Age-Related blindness | Lifespan.io
Feb 15, 2017 · LYSOCLEAR is an enzyme product that can enter the lysosomes of RPE cells where A2E accumulates and destroy it. Ongoing studies suggest that LYSOCLEAR is safe …See details»
World Renowned Eye Expert Dr. José-Alain Sahel, M.D. Joins …
As an Advisory Board member, Dr. Sahel will advise on the clinical trial design for therapies that Lysoclear is developing for dry AMD and Stargardt's macular degeneration, including the …See details»
Kelsey Moody Presenting on the LysoClear Program at ... - Fight …
Oct 14, 2019 · LysoClear is an example of the commercial development of a rejuvenation therapy, taken all the way from the starting point of the discovery of microbial enzymes capable of …See details»
Kelsey Moody Presenting on the LysoClear Program at Ending
Oct 19, 2019 · Kelsey Moody of Ichor Therapeutics presented on the LysoClear development program at the Ending Age-Related Diseases conference organized by the Life Extension …See details»
LYSOCLEAR for treating macular degeneration - lifespan.io
Ichor Therapeutics announced the launch of LYSOCLEAR, a therapeutic approach that proposes to reverse age-related macular degeneration and the related Stargardt macular degeneration.See details»
Ichor Life Sciences Invests $1.5 Million in Mitochem Therapeutics …
Aug 11, 2022 · MitoChem Therapeutics is the third company focusing on treatments for ocular disease in the Ichor portfolio, along with Lento Bio, Inc. and Lysoclear, Inc. Ichor has …See details»
Recombinant Manganese Peroxidase Reduces A2E Burden in Age …
Dec 17, 2018 · In this article, we present a proof-of-concept study for an enzyme-based therapy to remove these retinoids, modeled on traditional enzyme replacement therapy. Recombinant …See details»
LysoSENS: Clearing Waste Accumulations Out of Cells
Remarkably, just six weekly doses of LYSOCLEAR eliminated nearly a third of the A2E and similar stubborn wastes in the mice’s eyes. Unfortunately, the LYSOCLEAR program stalled …See details»
Antoxerene Closes $10 Million Deal with Juvenescence to Develop …
Proceeds from this work are used to support R&D initiatives that constitute Ichor’s portfolio companies in small molecule drug discovery (Antoxerene, Inc.), enzyme therapy (Lysoclear, …See details»